Several different models were found to be equally useful for predicting those at risk of progression in multiple myeloma.
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Additional research is needed on the best dose schedule for the drug.
Frameworks used to make prescribing decisions on checkpoint inhibitors may need to be refined for adjuvant trials.
The underuse of the procedure in this patient population was independent of tumor biology and socioeconomic factors.
Meta-analyses showed women appear to benefit more from treatment with a combination regimen consisting of a PD-1 inhibitor plus chemotherapy than men.
Patients with actionable molecular aberrations should be administered chemotherapy or targeted therapies prior to trying immunotherapies, researchers asserted.
No overall survival benefit has yet been seen with the regimen in RCC.
A preexisting CD8+ T-cell response may be predictive of benefit from checkpoint blockade in SCLC.
